BACKGROUND: The Japan integrated staging (JIS) score is recognized to be useful in managing hepatocellular carcinoma (HCC). We evaluated the effects of the causative virus in patients stratified by this system. METHODS: We compared clinicopathologic features, cumulative and tumor-free survival rates, and causes of death between 301 hepatitis C virus-positive patients (HCV group) and 60 hepatitis B virus-positive patients (HBV group). RESULTS: Among patients with low JIS scores (0 or 1), the proportions of patients with high aspartate and alanine aminotranferase activities, moderate-to-severe active hepatitis, and with cirrhosis were significantly higher in the HCV than in the HBV group. Among patients with high JIS scores (2 to 4), the proportion with moderate-to-severe active hepatitis was also significantly higher in the HCV group. In patients with low JIS scores, those in the HCV group had significantly lower tumor-free and cumulative survival rates than those in the HBV group. Although no patient in the HBV group died of causes other than liver disease (HCC or hepatic failure), some patients in the HCV group died of causes other than liver disease. The proportion of patients who died because of HCC recurrence tended to be higher among patients with high JIS scores than among patients with a low JIS score. CONCLUSIONS: The effects of viral status on survival outcomes are greatest in patients with JIS scores of 0 or 1.
BACKGROUND: The Japan integrated staging (JIS) score is recognized to be useful in managing hepatocellular carcinoma (HCC). We evaluated the effects of the causative virus in patients stratified by this system. METHODS: We compared clinicopathologic features, cumulative and tumor-free survival rates, and causes of death between 301 hepatitis C virus-positive patients (HCV group) and 60 hepatitis B virus-positive patients (HBV group). RESULTS: Among patients with low JIS scores (0 or 1), the proportions of patients with high aspartate and alanine aminotranferase activities, moderate-to-severe active hepatitis, and with cirrhosis were significantly higher in the HCV than in the HBV group. Among patients with high JIS scores (2 to 4), the proportion with moderate-to-severe active hepatitis was also significantly higher in the HCV group. In patients with low JIS scores, those in the HCV group had significantly lower tumor-free and cumulative survival rates than those in the HBV group. Although no patient in the HBV group died of causes other than liver disease (HCC or hepatic failure), some patients in the HCV group died of causes other than liver disease. The proportion of patients who died because of HCC recurrence tended to be higher among patients with high JIS scores than among patients with a low JIS score. CONCLUSIONS: The effects of viral status on survival outcomes are greatest in patients with JIS scores of 0 or 1.
Authors: S Kubo; K Hirohashi; H Tanaka; T Tsukamoto; T Shuto; T Ikebe; T Yamamoto; K Wakasa; S Nishiguchi; T Kuroki; H Kinoshita Journal: World J Surg Date: 2000-12 Impact factor: 3.352
Authors: S Kubo; K Hirohashi; H Tanaka; T Tsukamoto; T Shuto; T Yamamoto; T Ikebe; K Wakasa; S Nishiguchi; H Kinoshita Journal: Cancer Date: 2000-03-01 Impact factor: 6.860
Authors: S Ko; Y Nakajima; H Kanehiro; M Hisanaga; Y Aomatsu; T Kin; K Yagura; T Ohyama; K Nishio; K Ohashi; M Sho; T Yamada; H Nakano Journal: Ann Surg Date: 1996-11 Impact factor: 12.969
Authors: Y Shiratori; S Shiina; M Imamura; N Kato; F Kanai; T Okudaira; T Teratani; G Tohgo; N Toda; M Ohashi Journal: Hepatology Date: 1995-10 Impact factor: 17.425
Authors: E Giannini; D Risso; F Botta; P Romagnoli; F Malfatti; A Fumagalli; E Testa; E Podestà; B Chiarbonello; S Polegato; R Testa Journal: J Intern Med Date: 2004-03 Impact factor: 8.989